Caminnov is a biotechnoligical company dedicated to creating new tools and drugs. For detection or therapeutic interest, our research team develop single domain antibodies in two distinct domains: the environment and health. Many VHHs are currently in development and patents have been submitted.

Environment:

Caminnov specialized in the development of the single domain antibodies against small molecules (peptides, chemical molecules, toxins). In partnership with others teams, we have developed VHHs against chemicals molecules present in the environment (MW: 170 g/mol) and (MW: 120 g / mol).

Molecules

Glyphosate 

AMPA 

Ochratoxin 

Others toxins 

Health :

Caminnov has developed many VHHs in the field of inflammation (Interleukins…) and receptors (LDL receptor, Transferrin receptor, GPCRs….). The Company has experience in the development of VHHs in the treatment of a wide range of diseases, including inflammation, immuno-oncology and oncology.

P2X4

LGI protein 

CAV protein

GPCRs receptors 

Others proteins

 

Caminnov has developed a hybrid business model based on two types of growth:  

1.External collaboration

The Company has developped a platform, competences and expertise in various R&D areas and has  set up well-structured and equipped technological platforms. Caminnov mission is to make its highly innovative platform technology available to pharmaceuticals and biotechnology partners.

2. Internal development

Caminnov is building a pipeline of phage libraries and VHHs for internal development against GPCRs, Inflammation molecules. Interested in partnering with Caminnov ? please contact us

 

 

 

 

 

 

home